• Mashup Score: 0

    Background Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become firmly established in treatment algorithms and national guidelines for improving glycemic control in type 2 diabetes mellitus (T2DM).To report the findings from a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial, which was designed to assess the efficacy and safety of a novel DPP-4 inhibitor fotagliptin in treatment-naive patients with T2DM. Methods Patients with T2DM were randomized to receive fotagliptin (n = 230), alogliptin (n = 113) or placebo (n = 115) at a 2:1:1 ratio for 24 weeks of double-blind treatment period, followed by an open-label treatment period, making up a total of 52 weeks. The primary efficacy endpoint was to determine the superiority of fotagliptin over placebo in the change of HbA1c from baseline to Week 24. All serious or significant adverse events were recorded. Results After 24 weeks, mean decreases in HbA1c from baseline were -0.70% for fotagliptin, -0.72% for a

    Tweet Tweets with this article
    • #Fotagliptin, a novel #DPP4i, was non-inferior to active comparator #alogliptin yet superior to #placebo in patients with uncontrolled #type2diabetes A randomized, multicenter, double-blind, placebo-controlled, phase 3 trial from @SunYatsen_Uni https://t.co/Hd1Lbp4l2U https://t.co/hCbwheIC6i

  • Mashup Score: 0

    This cohort study compares the incidence of atrial fibrillation in patients with type 2 diabetes associated with use of sodium-glucose cotransporter-2 inhibitors with dipeptidyl peptidase-4 inhibitors or glucagonlike peptide-1 receptor agonists.

    Tweet Tweets with this article
    • Initiating treatment with #SGLT2i was associated with reduction in the risk of incident AF compared with #DPP4i (18%) and #GLP1-RA (10%) in older patients with #T2DM https://t.co/1JupyiEUMK @JAMANetworkOpen @JAMA_current @JavedButler1 @JJheart_doc @DLBHATTMD @FudimMarat https://t.co/FBAaL3hIbK